Faust Brings in €8M Bridge Financing, Aims For More
By James Etheridge
Wednesday, October 11, 2006
BioWorld International Correspondent
PARIS - Faust Pharmaceuticals, which is developing therapies for nervous system diseases, completed an €8.2 million insider bridge financing, which is intended to be the first tranche of a €25 million C round funding.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.